NEW YORK (GenomeWeb) – GenMark Diagnostics reported after the close of the market on Thursday that its third quarter revenues rose 28 percent, driven by strength in sales of its XT-8 eSensor multiplex molecular diagnostics system.

For the three months ended Sept. 30, the firm reported revenues of $10.8 million, up from $8.5 million a year ago, and beating the consensus Wall Street estimate of $10.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.